CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for ...
Lineage Cell Therapeutics (LCTX) announced the receipt of an induced pluripotent stem cell line containing hypoimmunity edits, from Factor ...
Ratings for Lineage Cell Therapeutics (AMEX:LCTX) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ...
Welcome to the Lineage Cell Therapeutics Third Quarter 2025 Conference Call. [Operator Instructions] An audio webcast of this call is available on the Investors section of Lineage's website at ...
Ratings for Lineage Cell Therapeutics (AMEX:LCTX) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of ...
CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (LCTX) (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback